LSP led a EURO 32 million investement in OxThera AB



Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based privately-held biopharmaceutical company, uses the proceeds to complete the Oxabact® development program for treatment of Primary hyperoxaluria.
   
Next to LSP, Ysios Capital from Spain, Sunstone Capital from Denmark, and Flerie Invest from Sweden participated in this investment round. In addition to new investors the current shareholders Kurma Partners, France, Idinvest Partners, France, Stiftelsen Industrifonden, Sweden, and Brohuvudet, Sweden also invested. This investment bolsters OxThera's position as a leader in developing therapies for Primary hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
 
"We are happy to announce that we have successfully completed the financing for the Oxabact® Phase III pivotal study in Primary hyperoxaluria," says Elisabeth Lindner, CEO of OxThera. "We are confident that Oxabact® will positively impact the lives of patients with this devastating disease," Elisabeth Lindner continues.
 
Oxabact® is an oral product, composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), designed for enteric elimination of plasma oxalate. A complete clinical development plan for Oxabact® has been presented in Protocol Assistance and End-of-Phase II meetings with EMA and FDA respectively.
 
Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If left untreated, the disease can cause kidney failure and premature death. The high medical need of PH is unmet to date. Currently, the sole available cure is a combined transplantation of liver and kidneys.
 
Oxabact® holds orphan drug designations in the EU and the US for the treatment of PH, and in EU for treatment of Short Bowel Syndrome (SBS).
 
About OxThera 
OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline; Oxabact® for the treatment of Primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for treatment of dietary hyperoxaluria and prevention of kidney stones. This research has received funding from the European Union´s Seventh Framework Programme managed by REA-Research Executive Agency (FP7/2007-2013) under grant agreement no FP7-SME-2013, see here
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact:
Martijn Kleijwegt
Managing Partner LSP
+31206645500
zxyrvwjrtg@yfcip.pbz
 
« back to overview
Follow us

LSP led a EURO 32 million investement in OxThera AB



Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based privately-held biopharmaceutical company, uses the proceeds to complete the Oxabact® development program for treatment of Primary hyperoxaluria.
   
Next to LSP, Ysios Capital from Spain, Sunstone Capital from Denmark, and Flerie Invest from Sweden participated in this investment round. In addition to new investors the current shareholders Kurma Partners, France, Idinvest Partners, France, Stiftelsen Industrifonden, Sweden, and Brohuvudet, Sweden also invested. This investment bolsters OxThera's position as a leader in developing therapies for Primary hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
 
"We are happy to announce that we have successfully completed the financing for the Oxabact® Phase III pivotal study in Primary hyperoxaluria," says Elisabeth Lindner, CEO of OxThera. "We are confident that Oxabact® will positively impact the lives of patients with this devastating disease," Elisabeth Lindner continues.
 
Oxabact® is an oral product, composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), designed for enteric elimination of plasma oxalate. A complete clinical development plan for Oxabact® has been presented in Protocol Assistance and End-of-Phase II meetings with EMA and FDA respectively.
 
Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If left untreated, the disease can cause kidney failure and premature death. The high medical need of PH is unmet to date. Currently, the sole available cure is a combined transplantation of liver and kidneys.
 
Oxabact® holds orphan drug designations in the EU and the US for the treatment of PH, and in EU for treatment of Short Bowel Syndrome (SBS).
 
About OxThera 
OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline; Oxabact® for the treatment of Primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for treatment of dietary hyperoxaluria and prevention of kidney stones. This research has received funding from the European Union´s Seventh Framework Programme managed by REA-Research Executive Agency (FP7/2007-2013) under grant agreement no FP7-SME-2013, see here
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact:
Martijn Kleijwegt
Managing Partner LSP
+31206645500
zxyrvwjrtg@yfcip.pbz
 
« back to overview